Asbestos exposure and survival in malignant mesothelioma: A description of 122 consecutive cases at an occupational clinic

International Journal of Occupational and Environmental Medicine

Volumn 2, Issue 4, 2011, Pages 224-236

  Skammeritz, E ^a   Omland, L H ^a   Johansen, J P ^a   Omland, O ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Asbestos; Exposure; Mesothelioma; Prognosis; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS;

AGED; AGRICULTURAL WORKER; ARTICLE; AUTOMOBILE INDUSTRY; BUILDING INDUSTRY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CEMENT INDUSTRY; DENMARK; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON AND STEEL INDUSTRY; KARNOFSKY PERFORMANCE STATUS; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; ORCHIECTOMY; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PLEURECTOMY; PROGNOSIS; SEROSA; SEX DIFFERENCE; SHIPYARD WORKER; SURVIVAL TIME; TESTIS CANCER; TUNICA VAGINALIS;

AGED; ASBESTOS; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MESOTHELIOMA; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONS; PLEURAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 80053040043     PISSN: 20086520     EISSN: 20086814     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Moore AJ, Parker RJ, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis 2008;3:34.
2. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-5.
3. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: The european organization for research and treatment of cancer experience. J Clin Oncol 1998;16:145-52.
4. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in ontario and quebec: A retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
5. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the north western cape province. Br J Ind Med 1960;17:260-71.
6. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J 1996;9:1932-42.
7. Bianchi C, Giarelli L, Grandi G, et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997;6:162-6.
8. McDonald JC, Sebastien P, McDonald AD, et al. Epidemiological observations on mesothelioma and their implications for non-occupational exposure.
9. Price B, Ware A. Time trend of mesothelioma incidence in the united states and projection of future cases: An update based on SEER data for 1973 through 2005. Crit Rev Toxicol 2009;39:576-88.
10. Kjaergaard J, Andersson M. Incidence rates of malignant mesothelioma in denmark and predicted future number of cases among men. Scand J Work Environ Health 2000;26:112-7.
11. Hillerdal G. Mesothelioma: Cases associated with non-occupational and low dose exposures. Occup Environ Med 1999;56:505-13.
12. Suzuki Y. Pathology of human malignant mesothelioma - preliminary analysis of 1.517 mesothelioma cases. Ind Health 2001;39:183-5.
13. Frank L. Epidemiology. when an entire country is a cohort. Science 2000;287:2398-9.
14. Burdorf A, Swuste P. An expert system for the evaluation of historical asbestos exposure as diagnostic criterion in asbestos-related diseases. Ann Occup Hyg 1999;43:57-66.
15. Kleinbaum DG KM. Extension of the cox proportional hazards model for time-dependent variables. In: Anonymous Survival Analysis: A Self-Learning Text. Springer Science+Business Media, IncNew York; 2005:211-56.
16. Britton M. The epidemiology of mesothelioma. Semin Oncol 2002;29:18-25.
17. Roggli VL, Sharma A, Butnor KJ, et al. Malignant mesothelioma and occupational exposure to asbestos: A clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002;26:55-65.
18. Hyland RA, Ware S, Johnson AR, et al. Incidence trends and gender differences in malignant mesothelioma in new south wales, australia. Scand J Work Environ Health 2007;33:286-92.
19. Bertazzi PA. Descriptive epidemiology of malignant mesothelioma. Med Lav 2005;96:287-303.
20. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: The SEER experience. Int J Cancer 1988;41:525-30.
21. Neumann V, Rutten A, Scharmach M, et al. Factors influencing long-term survival in mesothelioma patients--results of the german mesothelioma register. Int Arch Occup Environ Health 2004;77:191-9.
22. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma: Clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307-13.
23. Ak G, Metintas S, Metintas M, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol 2009;4:1425-30.
24. Metintas M, Metintas S, Ucgun I, et al. Prognostic factors in diffuse malignant pleural mesothelioma: Effects of pretreatment clinical and laboratory characteristics. Respir Med 2001;95:829-835.
25. Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east england: Clinicopathological experience of 272 cases. Thorax 1997;52:507-12.
26. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
27. Ribak J, Lilis R, Suzuki Y, et al. Malignant mesothelioma in a cohort of asbestos insulation workers: Clinical presentation, diagnosis, and causes of death. Br J Ind Med 1988;45:182-7.
28. Raffn E, Lynge E, Juel K, et al. Incidence of cancer and mortality among employees in the asbestos cement industry in denmark. Br J Ind Med 1989;46:90-6.
29. Reid A, Berry G, de KN, et al. Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite). Chest 2007;131:376-82.
30. Iyoda A, Yusa T, Kadoyama C, et al. Diffuse malignant pleural mesothelioma: A multi-institutional clinicopathological study. Surg Today 2008;38:993-8.
31. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: A retrospective study of 314 patients in the west part of japan. Jpn J Clin Oncol 2010;10:1093.
32. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and leukemia group B. Chest 1998;113:723-731.
33. Van GT, Damhuis RA, Hoogsteden HC. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7:1035-8.
34. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the dana-farber cancer institute and brigham and women's hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
35. Manzini VP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: A multicenter study on 81 cases. Ann.Oncol. 2010;21:348-53.
36. Wolf AS, Richards WG, Tilleman TR, et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 2010;90:949-56.
37. Ceresoli GL, Locati LD, Ferreri AJ, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001;34:279-287.
38. Yan TD, Popa E, Brun EA, et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006;93:1536-42.
39. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-24.
40. Gordon IO, Sitterding S, Mackinnon AC, et al. Update in neoplastic lung diseases and mesothelioma. Arch Pathol Lab Med 2009;133:1106-15.